Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Synthesis, Antiparasitic Activity, and ADME Profile of Morpholinephenylbenzamides: A Pharmacological Study Against Chagas Disease and Visceral Leishmaniasis

Chagas disease and leishmaniasis are neglected tropical diseases with limited treatment options. This study reports a hit‐to‐lead optimization of morpholinephenylbenzamides, starting from hit 1, which showed potent activity against Trypanosoma cruzi (IC50 0.29–0.76 μM) and Leishmania infantum (IC50 10.7 μM), despite a...

D. Farago, Daniela de Melo Resende, Mariza Gabriela Faleiro de Moura Lodi Cruz et al. · 0 citations
Aug 2026

Pre-clinical evaluation of (2E,5E)-2,5-bis(isoquinolin-5-ylmethylene)-cyclopentanone as a promising leishmanicidal agent.

Investigation of the safety and therapeutic potential of (2E,5E)-2,5-bis(isoquinolin-5-ylmethylene)cyclopentanone (ICP) against Leishmania infantum indicates that it represents an interesting chemical scaffold for further optimization and investigation toward the development of new treatments for leishmaniasis.

Isabela Cristina Soares Martins, T. T. Santos, C. Queiroz-Junior et al. · 0 citations
#gene editing Open access Sep 2026

Glycosomal ABC transporter 3 (GAT3) is associated with antileishmanial drug susceptibility in Leishmania infantum.

It is demonstrated that GAT3 is a non-essential glycosomal ABC transporter that contributes to antileishmanial drug susceptibility in L. infantum and the association between GAT3 deletion and reduced expression of AQP1 and MT suggests a previously unrecognized link between glycosomal transport processes and pathways in...

H. M. Costa-Silva, Davi Alvarenga Lima, Lisandra Chieza Souza et al. · 0 citations
Open access 2026

Furanocarboxamide Derivative Against Congenital Toxoplasmosis: Synthesis, Bioactivity, ADME Profile and in silico Insights

Overall, this work establishes compound 1 as a promising hit for congenital toxoplasmosis and malaria, providing a clear roadmap for future hit-to-lead optimization to overcome its current pharmacokinetic limitations.

J. O. Carvalho, Ana Paula C. Procópio, M. P. O. Almeida et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.